Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STE 
STERIS plc (STE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: STE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -20.53% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.89B USD | Price to earnings Ratio 34.18 | 1Y Target Price 250.13 |
Price to earnings Ratio 34.18 | 1Y Target Price 250.13 | ||
Volume (30-day avg) 556319 | Beta 0.88 | 52 Weeks Range 195.87 - 246.95 | Updated Date 04/4/2025 |
52 Weeks Range 195.87 - 246.95 | Updated Date 04/4/2025 | ||
Dividends yield (FY) 1.03% | Basic EPS (TTM) 6.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.66% | Operating Margin (TTM) 18.33% |
Management Effectiveness
Return on Assets (TTM) 5.59% | Return on Equity (TTM) 9.61% |
Valuation
Trailing PE 34.18 | Forward PE 24.45 | Enterprise Value 23918422192 | Price to Sales(TTM) 3.87 |
Enterprise Value 23918422192 | Price to Sales(TTM) 3.87 | ||
Enterprise Value to Revenue 4.43 | Enterprise Value to EBITDA 17.29 | Shares Outstanding 98250800 | Shares Floating 97877436 |
Shares Outstanding 98250800 | Shares Floating 97877436 | ||
Percent Insiders 0.29 | Percent Institutions 96.28 |
Analyst Ratings
Rating 3.89 | Target Price 248.26 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
STERIS plc
Company Overview
History and Background
STERIS plc was founded in 1985 as Innovative Medical Technologies, Inc., later renamed STERIS Corporation. It grew through acquisitions and organic expansion to become a leading provider of infection prevention and surgical products and services.
Core Business Areas
- Healthcare: Provides sterilization products, services, and equipment for hospitals and healthcare facilities.
- Applied Sterilization Technologies: Offers contract sterilization and lab services for medical devices and pharmaceutical companies.
- Life Sciences: Provides cleaning, sterilization, and contamination control solutions for pharmaceutical, biopharmaceutical, and research markets.
Leadership and Structure
STERIS plc is led by its Chief Executive Officer, Dan Carestio, and is structured with a Board of Directors overseeing the company's strategic direction. It operates through various business units, each responsible for a specific product or service area.
Top Products and Market Share
Key Offerings
- Sterilizers: Steris offers a variety of sterilizers, including steam sterilizers, low-temperature sterilizers (VHP, EtO), and washer-disinfectors. Competitors include Getinge and Cantel Medical (now part of Sotera Health). Market share for steam sterilizers is estimated at 30% (based on analysis of hospital contracts and revenue reports).
- Disinfectants: Steris offers a wide range of disinfectants, detergents, and cleaning products. Market share is estimated at 20%. Competitors include Ecolab, Diversey, and PDI Healthcare.
- Surgical Tables: Steris offers surgical tables and related equipment used in operating rooms. Market share is estimated at 25%. Competitors include Getinge, Maquet (Getinge), and Mizuho OSI.
- Contract Sterilization Services: Contract sterilization and lab services that serve medical devices, pharmaceutical and biopharmaceutical companies. No market share data available. Competitors include Sotera Health and Nelson Labs.
Market Dynamics
Industry Overview
The infection prevention and sterilization market is driven by increasing healthcare spending, stringent regulatory requirements, and growing awareness of healthcare-associated infections (HAIs). The market is competitive, with several large players and niche providers.
Positioning
STERIS plc is a leading player in the infection prevention and sterilization market, with a strong global presence and a comprehensive product and service portfolio. Its competitive advantages include its established brand, diverse offerings, and strong customer relationships.
Total Addressable Market (TAM)
The global sterilization services and infection control market size is expected to reach $25 billion USD by 2028. STERIS plc is well-positioned to capture a significant portion of this TAM, focusing on healthcare, applied sterilization and Life Sciences end markets.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diversified product and service portfolio
- Global presence
- Established customer relationships
- Consistent revenue growth
Weaknesses
- Reliance on healthcare spending
- Exposure to regulatory changes
- Integration risks from acquisitions
- High valuation relative to peers
Opportunities
- Expanding into emerging markets
- Developing innovative products and services
- Acquiring complementary businesses
- Increased outsourcing of sterilization services
- Growing aging populations
Threats
- Intense competition
- Pricing pressures
- Economic downturns
- Changes in healthcare regulations
- Patent expirations
Competitors and Market Share
Key Competitors
- GETI
- SOTERA HEALTH
Competitive Landscape
STERIS plc faces competition from large, diversified healthcare companies and smaller, niche providers. Its competitive advantages include its comprehensive product portfolio, global presence, and strong customer relationships. Disadvantages may include a higher valuation compared to some peers and potential integration risks from acquisitions.
Major Acquisitions
Cantel Medical
- Year: 2021
- Acquisition Price (USD millions): 4600
- Strategic Rationale: Expanded STERIS plc's endoscope reprocessing business and broadened its product portfolio.
Key Surgical
- Year: 2018
- Acquisition Price (USD millions): 850
- Strategic Rationale: Enhanced STERIS plc's sterile processing workflow solutions and added complementary products and services.
Growth Trajectory and Initiatives
Historical Growth: STERIS plc has demonstrated consistent revenue and earnings growth over the past decade, driven by organic expansion and acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for STERIS plc, driven by increasing healthcare spending and demand for infection prevention products and services.
Recent Initiatives: Recent initiatives include strategic acquisitions, new product launches, and expansion into emerging markets.
Summary
STERIS plc is a strong player in the infection prevention and sterilization market, benefiting from a diversified product portfolio and global presence. While facing competition and potential regulatory headwinds, it has shown consistent growth through acquisitions and organic expansion. High valuation, potential integration risk, and reliance on healthcare spending are key aspects the company needs to manage. The company is positioned well for continued success.
Similar Companies
MMM
3M Company
MMM
3M Company
SHC
Sotera Health Co
SHC
Sotera Health Co
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Research Reports
- Company Investor Presentations
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice and should not be used as the sole basis for making investment decisions. Market conditions can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STERIS plc
Exchange NYSE | Headquaters Mentor, OH, United States | ||
IPO Launch date 1992-06-01 | President, CEO & Director Mr. Daniel A. Carestio | ||
Sector Healthcare | Industry Medical Devices | Full time employees 18000 | Website https://www.steris.com |
Full time employees 18000 | Website https://www.steris.com | ||
STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.